EFFICACY AND SAFETY OF MIRIKIZUMAB AS INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 LUCENT-1 STUDY

被引：0
|
作者：
D'Haens, Geert
Kobayashi, Taku
Morris, Nathan
Lissoos, Trevor
Hoover, Amy
Li, Xingyuan
Arora, Vipin
Milch, Catherine
Sandborn, William J.
Sands, Bruce E.
机构：
来源：
GASTROENTEROLOGY | 2022年 / 162卷 / 07期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
884
引用
收藏
页码：S214 / S214
页数：1
相关论文
共 50 条
  • [31] EFFICACY AND SAFETY OF FILGOTINIB AS INDUCTION THERAPY FOR PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 2B/3 SELECTION STUDY
    Feagan, Brian G.
    Loftus, Edward V.
    Danese, Silvio
    Vermeire, Severine
    Sandborn, William J.
    Ritter, Timothy E.
    Mehta, Rajiv
    Seidler, Ursula
    Seibold, Frank
    Beales, Ian
    Kim, Hyo Jong
    McNally, John
    Yun, Chohee
    Zhao, Sally
    Liu, Xiaopeng
    Tasset, Chantal T.
    Besuyen, Robin
    Watanabe, Mamoru
    Schreiber, Stefan
    Rogler, Gerhard
    Hibi, Toshifumi
    Peyrin-Biroulet, Laurent
    GASTROENTEROLOGY, 2021, 160 (06) : S125 - S125
  • [32] Association of Bowel Urgency With Quality-of-Life Measures in Patients With Moderately-to-Severely Active Ulcerative Colitis: Results From Phase 3 LUCENT-1 (Induction) and LUCENT-2 (Maintenance) Studies
    Long, Millie D.
    Schreiber, Stefan
    Hibi, Toshifumi
    Gibble, Theresa Hunter
    Fisher, Deborah A.
    Park, Gina
    Moses, Richard E.
    Higgins, Peter D. R.
    Lindsay, James O.
    Lee, Scott D.
    Escobar, Rodrigo
    Jairath, Vipul
    CROHNS & COLITIS 360, 2024, 6 (01)
  • [33] Mirikizumab Achieved Comprehensive Disease Control in Patients With Ulcerative Colitis From Phase 3 LUCENT-1 and LUCENT-2 Trials
    Navabi, Seyedehsan
    Schreiber, Stefan
    Keohane, Anthony
    Baygani, Simin
    Gibble, Theresa Hunter
    Wu, Jianmin
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2023, 118 (10): : S684 - S685
  • [34] Efficacy and safety of the mirikizumab extended induction cohort at 152 weeks of continuous treatment for moderately to severely active Ulcerative Colitis: Results from the LUCENT-3 open-label extension study
    Hart, A.
    Blumenstein, I
    Kobayashi, T.
    Chaparro, M.
    Fantini, M. C.
    Fumery, M.
    Keohane, A.
    Dhesi, E.
    Tian, T.
    Redondo, I
    Barnes, E. L.
    JOURNAL OF CROHNS & COLITIS, 2025, 19 : i1452 - i1454
  • [35] THE EFFICACY AND SAFETY OF GUSELKUMAB AS MAINTENANCE THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 QUASAR MAINTENANCE STUDY
    Rubin, David T.
    Allegretti, Jessica R.
    Panes, Julian
    Shipitofsky, Nicole
    Yarandi, Shadi
    Huang, Kuan-Hsiang G.
    Germinaro, Matthew
    Wilson, Rebbecca
    Zhang, Hongyan
    Feagan, Brian G.
    Hisamatsu, Tadakazu
    Lichtenstein, Gary R.
    Bressler, Brian
    Peyrin-Biroulet, Laurent
    Sands, Bruce E.
    Dignass, Axel
    GASTROENTEROLOGY, 2024, 166 (05) : S180 - S180
  • [36] THE EFFICACY AND SAFETY OF GUSELKUMAB INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: PHASE 213 QUASAR STUDY RESULTS THROUGH WEEK 12
    Allegretti, Jessica R.
    Rubin, David T.
    Bressler, Brian
    Huang, Kuan-Hsiang G.
    Shipitofsky, Nicole
    Germinaro, Matthew
    Zhang, Hongyan
    Johanns, Jewel
    Feagan, Brian
    Sandborn, William J.
    Sands, Bruce E.
    Hisamatsu, Tadakazu
    Lichi, Gary R.
    Lichtenstein, Gary R.
    Panes, Julian
    Dignass, Axel
    GASTROENTEROLOGY, 2022, 162 (07) : S963 - S964
  • [37] Extended Induction of Mirikizumab Sustains Efficacy and Safety Over 104 Weeks for Patients With Moderately to Severely Active Ulcerative Colitis Refractory to Initial Induction
    D'Haens, Geert
    Navabi, Seyedehsan
    Chan-Diehl, Faye
    Moses, Richard E.
    Walter, James
    Gibble, Theresa Hunter
    Laharie, David
    Gisbert, Javier P.
    Vermeire, Severine
    Kobayashi, Taku
    Regueiro, Miguel
    Johns, Jordan
    Charabaty, Aline
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2023, 118 (10): : S871 - S872
  • [38] Risankizumab Maintenance Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: Efficacy and Safety in the Randomised Phase 3 COMMAND Study
    Louis, E.
    Panaccione, R.
    Parkes, G.
    Peyrin-Biroulet, L.
    Ferrante, M.
    Hisamatsu, T.
    Siegmund, B.
    Kalabic, J.
    Levine, P.
    Neimark, E.
    Wallace, K.
    Chen, S.
    Cheng, L.
    Duan, W. R.
    Armuzzi, A.
    Biederman, L.
    Loftus, E.
    Melmed, G.
    Schreiber, S.
    JOURNAL OF CROHNS & COLITIS, 2024, 18 : I10 - I12
  • [39] Efficacy and safety of mirikizumab as induction and maintenance treatment in adults 60 years or older with moderately to severely active ulcerative colitis
    Sturm, A.
    Sebastian, S.
    Faye, A. S.
    Armuzzi, A.
    Buisson, A.
    Halfvarson, J.
    Zeissig, S.
    Kochar, B.
    Maier, S.
    Redondo, I
    Moses, R. E.
    Keohane, A.
    Watanabe, K.
    JOURNAL OF CROHNS & COLITIS, 2025, 19 : i2005 - i2006
  • [40] EXTENDED TREATMENT WITH MIRIKIZUMAB IN PATIENTS WITH MODERATELY-TO-SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM A PHASE 2 TRIAL
    Sandborn, William J.
    Ferrante, Marc
    Bhandari, Bal R.
    Berliba, Elina
    Hibi, Toshifumi
    D'Haens, Geert R.
    Tuttle, Jay
    Krueger, Kathryn A.
    Friedrich, Stuart
    Durante, Michael
    Arora, Vipin
    Feagan, Brian G.
    GASTROENTEROLOGY, 2019, 156 (06) : S1094 - S1094
12345